Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
Giulia SciosciaPasquale TondoSanti NolascoCorrado PelaiaGiovanna Elisiana CarpagnanoMaria Filomena CaiaffaGiuseppe ValentiAngelantonio MaglioFrancesco PapiaMassimo TriggianiNunzio CrimiGirolamo PelaiaAlessandro VatrellaMaria Pia Foschino BarbaroClaudia CrimiPublished in: Journal of clinical medicine (2023)
Patients diagnosed with severe eosinophilic asthma who experience a partial response to mepolizumab could benefit from switching to benralizumab, and even more those who have nasal polyposis.
Keyphrases
- chronic rhinosinusitis
- end stage renal disease
- chronic obstructive pulmonary disease
- lung function
- ejection fraction
- early onset
- newly diagnosed
- chronic kidney disease
- clinical trial
- allergic rhinitis
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- cystic fibrosis
- patient reported